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ABSTRACT 
Formulation Development of a Polymer-Drug Matrix With a 
Controlled Release Profile for the Treatment of Glaucoma 
 
Eric Tsoi 
 
Glaucoma is the leading cause of blindness in the United States accounting for 9-
12% of all cases of blindness. Currently, the front line treatment for glaucoma are 
prostaglandins that may have to be taken up to several times a day. Even with proper 
treatment, roughly 11% of the patients using the treatment are non-compliant and lose 
their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug 
delivering implant with the capability of sustaining long-term release of a prostaglandin 
as a new way to treat the condition. This project reports the product development of a 
polymer drug matrix with a controlled release in order to better treat glaucoma. 
Accompanying product development, a mathematical model was created in order to 
strengthen the understanding of the dosage profile and to predict long term dosages. 
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1. Background of Project 
Glaucoma is the leading cause of blindness in the United States and typically affects 
people over the age of 60. It is estimated that between 1 and 3 percent of the white and 
Asian population and between 3 and 9 of the black population will develop primary 
open angle glaucoma (POAG), the most common form of glaucoma. By 2020, 600,000 
people worldwide are estimated to go blind from the disease annually.  
Intraocular pressure (IOP) is responsible for maintaining the globular shape of the 
eye and plays a key role in glaucoma. IOP is determined by three factors: 
1. The rate of aqueous humor production. 
2. Resistance to aqueous outflow across the trabeculum, especially in the 
juxtacanalicular meshwork, and  
3. The level of episcleral venous pressure. 
Patients typically exhibit fluctuations in IOP throughout the day. Normally the IOP is 
in a state of equilibrium fluctuating between 12 and 20mmHg. Typical daily IOP profiles 
are seen in Figure 1.1. Some patients exhibit a morning rise, where their IOP is 
significantly elevated in the morning. Others exhibit an inverse IOP variation, with an 
afternoon rise of IOP, while others may exhibit a biphasic diurnal change in IOP with two 
distinct IOP rises and falls during the day 
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Figure 1.1 Diurnal Fluctuations in IOP (Nema, 2012) 
Glaucoma is a group of conditions that affect the optic nerve. In the majority of 
cases, damage to the optic nerve is caused by increase in IOP due to inadequate flow of 
aqueous humor, as illustrated in Figure 1.2. 
   
Figure 1.2 Pressure Inside the Eye Due to Aqueous Humor Build-Up (Samuels, 2013) 
Aqueous humor is produced inside the anterior chamber of the eye and flows 
through the interior and posterior chambers. The majority (85-95%) of outflow from the 
eye occurs through the trabecular meshwork-Schlemm’s canal-venous system route in 
the anterior chamber of the eye. A closer look at the anterior chamber is illustrated in 
Figure 1.3 below. The angle of the anterior chamber is necessary in understanding the 
mechanisms of glaucoma. The angle is created between the anterior chamber being 
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anteriorly bounded by the posterior surface of the cornea and posteriorly by the 
anterior surface of the iris and the anterior surface of the lens. The angle of the anterior 
chamber is a peripheral recess formed by the root of the iris and part of the ciliary body 
(Figure 1.3). 
 
Figure 1.3 Anatomy of the Anterior Chamber and its Angle (Nema, 2012) 
While surgical treatments for glaucoma are available, glaucoma medications, in the 
form of eye drops, are used as front-line treatments. Medications used to treat 
glaucoma include: 
1. Prostaglandins – latanaprost (Xalatan), bimatoprost (Lumigan) and tafluprost 
(Zioptan) 
2. Beta-Blockers – timolol (Timoptic, Betimol) 
3. Carbonic Anhydrase Inhibitors – dorzolamide (Trusopt) 
4. Alpha Agonists – apraclonidine (lopidine) and brimondidine (Alphagen) 
Prostaglandins are hormone like substances that help widen blood vessels by 
mimicking natural prostaglandins in order to increase the drainage of aqueous humor to 
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help reduce IOP. Prostaglandins are typically the first medication used to treat 
glaucoma. Beta-blockers lower the pressure inside the eye by inhibiting the production 
of aqueous humor. Beta- blockers are usually administered in higher dosages relative to 
prostaglandins because only a small amount of the drug is absorbed by the cornea while 
the rest enters the bloodstream and cause adverse side effects such as lowered heart 
rate and interference with other beta-blocker medications. Carbonic anhydrase 
inhibitors (CAIs) are normally prescribed when other glaucoma drugs do not work. CAIs 
reduce the rate of aqueous humor production and may improve blood flow in the retina 
and optic nerve. Alpha agonists reduce the production of aqueous humor and increase 
drainage.  
To combat this condition, ForSight Labs has been developing a way to minimize non-
compliance to current glaucoma treatments. ForSight Labs is a center for innovating 
ophthalmic products and aims to develop a product that will change the way glaucoma 
is treated. Their vision statement is reproduced below: 
“ForSight Labs is focused on developing and applying solutions to improve the sight, 
care, and quality of life of visually impaired patients. Our environment is creative and 
collaborative; a place where entrepreneurs and investors work together to drive 
innovative technologies through concept, development, and ultimately 
commercialization in high-impact eye care companies  
Each day millions of people rely on their vision and suffer when it is lost. There are 
few disabilities as impactful to quality of life as the loss of vision. The number of people 
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with impaired vision in the US, including blindness, is expected to more than double 
over the next three decades. Recent estimates of the cost of vision loss in the US exceed 
$50 billion dollars annually. ForSight Labs brings together highly motivated and capable 
team members, clinicians and investors focused on starting and sustaining efforts to 
deliver innovative solutions to the ophthalmic community and the patients it serves.”  
ForSight Vision5 is developing an Ocular Insert capable of treating POAG. This 
project report outlines the developmental phase of a product capable of applying an 
active pharmaceutical ingredient (API) into the eye for the sustained release of an 
efficacious dose over a long period of time. The goal of the pilot product is to treat 
Glaucoma patients by effectively decreasing intraocular pressure in the eye by 30% or 
greater. 
This project report aims to highlight the early stages of development of a polymeric 
drug releasing device. Following initial development, process parameters were 
optimized for a larger scale production and a desired performance profile. After 
development of a product, the degree of control over its performance is highlighted 
with the application of an empirically derived mathematical model. 
The goal of the project is to develop a device capable of releasing an efficacious dose 
of an API for at least 120 days and develop a model that could accurately (>90%) 
forecast the release profile of the device. The mathematical model of the release rate 
profile was created to address a bottleneck of R&D and minimized the length of time 
empirically derived data is necessary. Throughout the product development cycle, 
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studies were employed to test proper wash conditions and other situations to which the 
Insert will be subjected in hopes of formulating a controlled release. The model allowed 
for this bottleneck to diminish from up to 180 days to 28 days.  
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2. Production of an Ocular Insert 
2.1. Product development 
 
Figure 2.1 The Medical Device Development Pathway (CDRH Innovation Initiative, 2011) 
 
In the medical device development pathway (Figure 2.1), the first step towards 
bringing a product to market is discovery and ideation. The regulatory process affects a 
significant portion of the device development pathway and should accommodate the 
iterative, cyclical nature of device design and development. At ForSight Laboratories, 
the focus is to achieve proof of concept through research and development of a 
product.  One of the first hurdles of the development pathway begins with proof of 
concept.  A good proof of concept should ideally be very cheap and easy to manufacture 
while sufficiently solving the problem at hand. The cost of the product is one factor that 
will determine the viability of the product and if it will move into the next stages of 
development. 
Fabrication of the device involved five main steps: formulation, molding, 
assembly, washing, and packaging and sterilization. Formulation of a polymer/drug 
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matrix requires a delicate blend of the starting materials in order to achieve a 
homogenous formulation with a desired physical properties for ease of handling. 
Molding of the formulation is achieved by using a mold milled in a computer numerical 
controlled (CNC) machine and filled through a transfer press tailored to achieve an 
optimal fill. In order to finalize the product, the molded segments must be assembled. 
Assembly requires the use of an optical microscope and soldering iron to build the final 
ocular insert. Washing treats the product in order to reduce its bio burden and leads to 
a product with the desired release rate profile. Packaging and sterilization are necessary 
steps to finalize the product packaging prior to use. 
Throughout the process, quality control maintains that the process and system 
under which all changes are done by maintaining a quality document system where 
everything is properly documented according to FDA compliance standards. Failure to 
adhere to quality control standards may result in failing FDA approval.  
2.2. Formulation of a Drug Polymer Matrix 
Silicone was chosen as a material to be used for sustained delivery of an 
appropriate API because of its chemical inertness, biocompatibility, ease of fabrication, 
and appropriate mechanical strength. Silicones can be designed with various cure 
chemistries to accommodate various product needs. Silicone systems can be cured by 
platinum catalyzed addition reactions, tin catalyzed condensation reactions, or peroxide 
and oxime reactions. Among all the different cure chemistries, the platinum catalyzed 
silicone systems contain no volatile byproducts and have fast curing rates. A platinum 
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catalyzed silicone system from our sourced supplier was selected for formulating 
sustained release products (Figure 2.2). 
 
Figure 2.2 Silicone Cross-Linking (DOW Corning, 2013) 
During the early stage of product development, a 7% drug loaded matrix 
produced the desired sustained release rate. The 7% drug-matrix was formulated using 
proprietary methods. Over time, a higher dosage with a longer release rate profile was 
desired. With the higher dosage form, a new formulation was developed since direct 
scaling up of the 7% formulation was not feasible. 
The matrix approach was chosen over a reservoir approach for formulating the API 
into the silicone mainly due to the ease of manufacturing. The drug is mixed 
homogenously into the silicone and then molded into the desired geometry using well-
established conventional molding equipment. Sustained release formulations with a 
range of drug loadings in silicones of different hardness have been evaluated. 
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2.3. Molding 
Initially, molds were produced in batches of 20 segments. Molding development 
investigated diameters as well as designs of the final product. As manufacturing was 
developed, a higher production rate was desired resulting in a 40-up mold capable of 
producing double the segments per transfer press cycle. The silicone segments were 
injection molded and cured at elevated temperature using quality control approved 
process instructions as guidance. 
2.4. Assembly 
After the silicone formulation is molded into segments, they must be assembled 
into the final product. For every ocular insert produced, two segments are needed. 
Assembly requires the proper training of operators in order to have a high degree of 
reproducibility. Manufacturing development introduced more automated aspects of the 
process; however, operators remained essential to producing a viable ocular insert 
(Figure 2.3).  
  
Figure 2.3 Assembly Process 
11 
 
2.5. Wash 
Once the product is assembled, each insert is treated in order to produce a final 
product with the desired release rate profile. The development of the wash method was 
a large focus of the research and development phase. The ideal release rate has a zero-
order profile over the length of time that drug is to be released. This is normally 
achieved through a reservoir system where the reservoir constantly feeds drug through 
an inert shell to the media. The inert shell is necessary to act as a rate limiting gradient; 
otherwise a high burst of drug would be seen. Since the design of the product utilizes a 
drug matrix instead of a reservoir system, an initial burst of drug was unavoidable. In 
order to mitigate the burst, washing is necessary. It was found that washing in water at 
elevated temperature for several days was needed to achieve the desired release rate of 
API at early time periods. 
2.6. Packaging and Sterilization 
Each ocular insert was then packaged in a plastic tray and sealed in a foil pouch as 
shown in Figure 2.4.  The packaged inserts were then sterilized via irradiation at a 
commercial e-beam facility at a sterilizing dose of 17.5 kGy. 
 
Figure 2.4 Pouching 
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3. Product Testing 
Test methods were developed to assure that each insert is made as uniformly as 
possible. The two main modes of testing the chemistry of the product are through 
Content Uniformity and Assay and Impurities Determination, and Release Rate testing. 
Generic results in the form of high performance liquid chromatography (HPLC) 
chromatograms are included to show what typical responses would be from the HPLC 
outputs. Actual results can be seen in the model development sections of this report.  
3.1. Content Uniformity and Assay and Impurities Determination 
3.1.1. Background 
An HPLC analytical assay method for determining the API content and related 
impurities in Ocular Inserts was developed. The API and its impurities are analyzed by 
gradient reversed-phase HPLC with UV detection at 210nm. 
3.1.2. Methods and Materials 
An  Agilent 1100 High Pressure Liquid Chromatographic System consisting of a 
high pressure pump, and inline degasser, a column compartment with thermostat, an 
autosampler, a UV absorbance detector, and an automated data collection system was 
used for sample analysis. The HPLC column consisted of a Zorbax Eclipse Plus C-18, 
3.5μm, 4.6mm X100mm. All solvents used were HPLC grade. The API and API related 
impurities and standards were supplied by the API manufacturer. 
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3.1.3. Procedure 
Mobile phase A for the HPLC was methanol/acetonitrile/water (10/10/80 v/v/v) 
with 0.05% H3PO4. The solution was mixed well prior to use.  
Mobile phase B for the HPLC was methanol/acetonitrile/water (10/40/50 v/v/v) 
with 0.05% 85% H3PO4. The solution was mixed well prior to use.  
Diluent Solution was methanol/acetonitrile/water (14/14/72 v/v/v. The solution 
was mixed well prior to use. 
API reference standard was prepared at a concentration of ~150μg/mL. This was 
achieved by accurately weighting 7.50mg of API into a 50mL volumetric flask. The flask 
was filled up half way with diluent solution and diluted to the mark with water (the 
diluent amount is negligible and aids the dissolution of API in the solvent). Two 
standards were produced in the same fashion and labeled as “Working Standard” and 
“Check Standard.” The nominal concentrations of the standards were determined using 
the following equation: 
Standard concentration (μg/mL) = 
𝑊𝑠 𝑋 𝑃 𝑋 1000
𝑉
, 
Where: 
Ws = Recorded weight of API or Ref Standard (mg) 
P = Purity of API based on Certificate of Analysis (CofA) for that particular lot 
V = Size of the volumetric flask (mL) 
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1000 = conversion factor for mg to μg 
 An LOQ (Limit of Quantitation) Standard was prepared at a concentration of 
~0.15μg/mL. Into a 50mL volumetric flask, 50μL of API Stock Standard solution 
(~150μg/mL) was pipetted. The flask was diluted with Diluent Solution and mixed well 
prior to use.  
 API resolution solutions of the impurities were prepared by first preparing stock 
solutions  at a ~10μg/mL concentration by pipetting 10μL of API related impurity stock 
solutions into 10mL of 2-propanol (IPA) in a glass vial and mixed well prior to use. 
Resolution solutions were prepared by pipetting 40μL of the API related impurity 
solutions into an HPLC vial, 20μL of API stock standard solution (~150μL/mL) and 170μL 
of water into the same vial. The vial was mixed using a vortex shaker prior to use.  
 For content uniformity analysis, samples were prepared by placing ~70mg of 
cured drug-matrix into a 40mL glass vial referred to as the stock sample vial. To each 
vial, at least 20ml of dichloromethane (DCM) was added and the vial was sonicated for 
100 minutes. All pieces of the drug-matrices were placed into 40mL glass vials already 
containing 5mL of DCM. The 40mL vials were sonicated for 10minutes and mixed for 5 
seconds. The 5mL solutions were transferred into the 20mL solutions. The solutions 
were then dried at 37oC inside a fume hood by utilizing nitrogen gas to expedite the 
evaporation process. After the samples were fully dried, a glass pipette was used to 
reconstitute the residual with 25mL of methanol. The caps were placed on and 
tightened and sonicated for 5 minutes to achieve complete dissolution. This solution 
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was stored at 2-8oC when not in use. Final sample preparation involved diluting 1mL of 
the sample solution with 2mL of water.  
 For assay and impurities, up to 10 individual samples were combined as a 
composite. Drug-matrices were cut into sizes which fit into a 40mL glass vial. At least 
30mL of DCM was added into glass vials in order to completely immerse the pieces. The 
vials were capped tightly and sonicated for 100minutes. Sonication steps identical to 
content uniformity were followed (e.g. 30mL + 5mL DCM). Final solution was prepared 
by adding 1mL of the stock sample to a 10mL volumetric flask. The flask was filled with 
Diluent solution to volume. 
 The HPLC chromatographic conditions were a flow rate of 0.7mL per minute with 
an injection volume of 20μL, a column temperature of 50oC, a detection wavelength of 
210nm, and a total run time of 20minutes. (Due to the use of a previously approved 
pharmaceutical, the known impurities generated have an absorbance at ~190nm. Since 
this wavelength tends to be very noisy when using a photodiode array detector, a more 
controllable wavelength was used). The gradient program is shown below in Table 3.1: 
Table 3.1 Gradient Program of Mobile Phase Mixing. 
Time (min) % Mobile Phase A %Mobile Phase B 
0 95 5 
1 95 5 
5 40 60 
16 40 60 
17 95 5 
20 95 5 
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 Chromatographic injection procedure followed equilibrating the HPLC system 
with mobile phase until a stable baseline is achieved. An injection of the working 
standard solution (~150μg/mL) may be done prior to starting the HPLC sequence to 
verify the retention time, USP tailing factor, and USP plate counts of the API peak. 
Mobile Phase A was injected at least once, followed by an injection of the diluent 
solution to ensure no interference with the API retention time. Sensitivity solution was 
injected to evaluate the method’s sensitivity. 
System Suitability  
 System Suitability parameters outline acceptance criteria for acceptable data. 
First a blank is injected to ensure no peak interference. Five working standard injections 
are prepared and must have a relative standard deviation of the retention time and 
peak areas within ±2%. Next, there is a sensitivity - LOQ check where the signal-to-noise 
ratio for the API yielded from the LOQ Standard injection must be ≥ 10. A standard 
confirmation is then necessary and is done by evaluating the response factor from the 
check standard injection for the API; it must be within 98% - 102% of the average 
response factor from the 5 replicate working standard injections. The percent difference  
% Difference =
Peak Area of Check Standard x Conc. of Working Standard
Avg. Peak Area of Workign Standard Injections x Conc. of Check Standard 
 X 100 
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The tailing factors of the API peak from all working standard injections must be 
≤ 2.The column efficiency is then checked by analyzing the column theoretical plate 
counts for the API peak from all the Working Standard injections and must be 
N ≥ 2000.The resolution factor for the API related impurity peaks relative to the API 
peak must be ≥ 1.5. The % difference of the peak areas for each bracketing standard 
must be ≤ 2% of the average peak area from the 5 replicate Working Standard 
injections.  
Sample calculations 
Measured API Content (µg) 
Calculate the response factor for each Working Standard 
RF =  
CStd
AStd
 
Where: 
RF   = Response factor (concentration/peak area) 
StdC  = Expected API concentration in Working Standard (µg/mL) 
StdA  = Peak area of API for Working Standard 
The concentration of the sample solution is calculated from the average 
response factor of the standard curve.  
AvgSmpSmp RFAC   
Where: 
SmpC  = Measured API concentration in sample (µg/mL) 
SmpA  = Peak area of API in sample (provided by HPLC) 
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AvgRF  = Average of the five response factors calculated for each Working Standard 
solution. 
The total API content in µg is calculated by multiplying the sample concentration 
by the total volume of MeOH and dilution factor.  
Measured API Content (µg) =  
DFVC SmpSmp   
Where: 
SmpC  = Measured API concentration in sample (µg/mL) 
SmpV  = Total volume of MeOH (e.g., 25 or 35 mL) 
DF    = Dilution factor (e.g., 3 or 10) 
 
API Assay 
The assay value for each content uniformity and assay sample is calculated by: 
 
 gLabelClaim
gContentAPIMeasured

 100
=Assay 

 
Where: 
For pre-cured mix and cured segments: Label Claim = Weight of sample x %API Loading  
For Ocular Inserts: Label Claim = as specified in Material Specification 
Impurity Calculations 
HPLC chromatograms of the API assay samples are compared to the HPLC 
chromatograms of the blanks (Diluent Solution and Mobile Phase A).  % Impurity are 
calculated based on the peak area of all peaks detected ≥ 0.1% peak area in the analysis 
region of the chromatogram. The API and API related impurities, along with any 
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extraneous peaks that meet the aforementioned criteria in the assay chromatograms of 
the samples must be accounted for in the total peak area. 
For each of the peaks detected, calculate its % purity by using the following 
formula: 
AreaPeakTotal
AreaPeak
Purity
100
%

  - % Impurities 
For known impurities, a response factor was determined relative to the main API 
response factor and used to calculate % Impurities.
 
3.1.4. Results and Discussion 
 Typical chromatograms achieved when analyzing samples for content uniformity 
and assay and impurities are reproduced below.  
 
Figure 3.1 Chromatogram of a Blank 
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Figure 3.2 Chromatogram of API Working Standard Solution (150 µg/mL) 
 
 
Figure 3.3 Chromatogram of LOQ (0.15 µg/mL) 
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Figure 3.4 Chromatogram of API and Impurities 
 
Figure 3.5 Chromatogram of Assay Sample 
3.2. Release Rate Kinetics  
3.2.1. Background 
Determining the drug release rate is achieved in a method similar to the assay 
and impurities methods. The API content in elution media at different time points was 
analyzed by a 5 minute HPLC. The release rate media were replaced with fresh 5mL of 
0.5% PBS/SDS solution at each testing time-point. 
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The purpose of this test method is to determine drug release rate (μg/day). The 
average daily drug release rate (μg/day) as well as the cumulative API released over an 
extended period will be determined by an in vitro test method developed by Forsight 
Vision5. API release is analyzed by reverse-phase HPLC with UV detection at 210 nm 
3.2.2. Methods and Materials 
An  Agilent 1100 High Pressure Chromatographic System as described previously 
was used for sample analysis. Rainin Pipet-Lite series L-5000, L-1000, L-200, and L-20 
pipets were used. A calibrated Mettler Toledo XS105 was used. An incubator set to 37oC 
was used to store samples. Class A volumetric glassware was used. Final samples were 
stored in HPLC vials with PTFE/Silicone Pre-Slit Septa caps. Reagents used include HPLC 
grade water, HPLC grade acetonitrile, HPLC grade methanol, HPLC grade phosphoric 
acid, phosphate buffered saline (PBS) pH 7.4, sodium dodecyl sulfate (SDS), and 
reference standards of API were used.  
3.2.3. Procedure 
 Release rate media was prepared by using 0.01M PBS solution with 0.05% SDS. 
Ocular inserts were weighed prior to use and placed in 15mL plastic vials. Into each 
plastic vial, 5mL of release media was added and the vials were capped. The start time 
was begun and considered as t=0. The vials were incubated at 37oC. At each of the 
sampling time points, samples were taken within 2 hours of the specified time point. 
The vials were gently swirled to ensure sample homogeneity. The release media was 
transferred from the sample vial into a separate clean vial and submitted for HPLC 
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analysis. Analyzed samples were stored indefinitely at ambient temperatures.  To the 
empty sample vials, and additional 5mL of release media was added. Incubation was 
continued at 37oC in an incubator until the next sampling time point. The amount of API 
obtained was recorded. The drug release rate (μg/day) and the cumulative amount was 
calculated at each time point. 
 HPLC diluent and API standards were prepared as following the method outlined 
in the assay and impurities section of testing. The mobile phase was 
methanol/acetonitrile/water (10/37/53, v/v/v) with 0.05% of 85% H3PO4. The increase in 
polarity of the solvents relative to the Content Uniformity and Assay and Impurities 
Determination in section 3.1 is utilized in order to increase the throughput of any drug 
particles. The method utilized a 5 minute isocratic run time. Calculations of peak areas 
to release rates were carried out in the same fashion as section 3.1. 
3.2.4. Results and Discussion 
The resulting peak areas from the chromatograms were used to calculate release 
rates. The release rate profiles were determined as µg/day in order to track the dosage 
of drug released into the eye. The release rate values are crucial to model development.  
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Figure 3.6 Chromatogram of Mobile Phase 
 
c  
Figure 3.7 Chromatogram of LOQ (0.15 µg/mL) 
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Figure 3.8 Chromatogram of API Working Standard Solution (15 µg/mL) 
 
 
 
Figure 3.9 Chromatogram of Release Solution Sample 
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4. Product Development 
After proof of concept has been established, and bench-top production has 
begun, the growth of the company occurs with pre-clinical investigations, regulatory 
filings, and clinical studies. During this stage, the goal for product development is to 
develop a product that can be made reproducibly with high quality so that pre-clinical 
and clinical evaluations generate valid results. While design changes fall under the realm 
of engineering, formulation and wash development fell under the realm of chemistry. 
4.1. Formulation Development 
Two formulation changes done to the product while scaling up batch production 
involved increasing the drug dose and changing the Durometer hardness of silicone. A 
higher drug loading was necessary in order to achieve a desired release rate. With the 
7% formulation, the product was only capable of sustaining the desired release rate for 
3 months. With higher drug loading, the product gives a higher release rate sustainable 
for up to 6 months. Saturation of the polymer matrix with the higher drug loading 
required different properties from the silicone in order to better contain the drug 
matrix.  
4.1.1. Effect of Drug Loading on Release Rate 
Formulation development first started with a Shore 10A durometer silicone. The 
loading of API into this silicone was varied from 5% up to 20%. Silicone segments with 
different drug loading were molded and API release rates monitored over a period of 3-
6 months. As anticipated from a matrix based formulation, there was an apparent 
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"initial burst" of drug, followed by a gradual decrease of release rate, eventually 
reaching a sustained steady-state level over time. 
The drug release rate was found to increase with an increase in drug loading, as 
shown in Figure 4.1. This appears to indicate concentration gradient driven drug 
diffusion across the silicone matrix 
 
Figure 4.1 Release Rate of API as a Function of Drug Loading 
A working hypothesis: The higher drug release rate for higher drug loading may 
be due to the higher drug concentrations near the surfaces of ocular inserts. In addition, 
as more drug gets loaded and dispersed in the insert, more "drug channels" may be 
formed in the silicone matrix that would facilitate drug release from the inner portion of 
the Ocular Insert, as illustrated in Figure 4.2. 
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Figure 4.2 Channel Formation in the Silicone Matrix Over Time (t) 
The drug release rate continues to decline over time even though the estimated 
cumulative drug release over the time period studied is around 16% drug loading, 
indicating that the distance drug molecules need to travel from the inner bulk of the 
insert to the surface also likely plays a role in drug release rate. 
Among all the different loadings in this silicone, 20% drug load appeared to meet 
the target drug release rate profile. However, the 20% API in these soft silicone inserts 
exhibited inconsistent mechanical properties and also appeared difficult to remove from 
the mold without breaking. 
4.1.2. Effect of Different Silicones on the Release Rate 
As an effort to improve the mechanical properties and manufacturability of the 
Ocular Inserts containing 20% drug load, a different silicone with the same cure 
properties, a higher durometer was tested with a Shore 30A hardness rating, and a 
tensile strength of 1350 psi compared to 750 psi for the initial 10A silicone (amongst 
other physical property differences). The silicone segments prepared at 20% load in this 
harder silicone appeared to have significantly improved mechanical strength and were 
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also easier to handle during manufacturing. Due to proprietary constraints, these two 
silicones will solely be referred to as 10A or 30A silicone. 
The surface morphologies of the silicone segments prepared with 10A silicone 
vs. 30A silicones are shown in Figure 4.3. It appeared that the silicone segments made 
with the harder silicone have much smoother surfaces than those made with the softer 
silicone. 
 
Figure 4.3 Surface Morphology of Silicone Segments Containing 20% API in Alternative 
Silicones 
Representative drug release rates of silicone segments containing 20% API in 
each of the silicones are presented in Figure 4.4. Both the silicones appear to result in 
similar release rate profiles, suggesting that silicone physical property differences have 
little impact on drug release from the silicone matrix. 
The slightly higher initial burst on day 1 for the softer silicone formulation may 
be related to surface deformities, which might have led to an effective increase in total 
surface area. A higher standard deviation in release rate is also observed for 20% API in 
the softer silicone, further supporting that a harder silicone is a better option for 
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formulating higher drug load because of more consistent drug release rate, less surface 
deformities, improved mechanical properties and ease of manufacturability. 
 
Figure 4.4 Release Rate of Ocular Insert Made with Silicones 10A and 30A 
4.2. Effect of Wash on the Release Rate 
 Once molded and assembled, the insert is treated with a washing step. Different 
wash conditions produced different release rates. After the wash method was 
established, modeling the release rate could be done in order to develop a more 
understandable product profile. 
Washing procedures were studied with Ocular Inserts and Silicone Segments 
with the goal of reducing the initial burst and obtaining a zero-order release rate profile. 
The results of the development of washing studies are shown below. 
4.2.1. Unwashed 7% API, 10A Silicone 
 The release rate of API from inserts made with 10A silicone and 7% drug loading, 
without washing is shown below in Figure 4.5.  
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Figure 4.5 Unwashed Release Rate 
 
 While this design demonstrated a potentially acceptable release rate profile, a 
lower initial release rate was desired. The goal of the following studies was to find the 
ideal washing conditions that would reduce the Day 1 burst and achieve a zero-order 
release rate profile.  
4.2.2. 7% API/10A Silicone Matrix Water Washing Studies 
Silicone Segments made with 10A silicone and 7% API loading were washed for 
different lengths of time with water, followed by a 15 minute 70% IPA wash and a 
1 minute 70% IPA rinse. The results for the non-irradiated silicone segments are shown 
below in Figure 4.6. 
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Figure 4.6 Effect of Water Wash Length on Release Rate 
Silicone segments washed with water have a lower burst when compared to samples 
washed with IPA only (see Figure 4.7). The results also indicated that a longer water 
wash will result in a lower initial burst and release rate. However, the effect of this 
appears to be lessened as the wash length increases (i.e., there is a larger difference 
between a 20 hour and 48 hour water wash compared to the difference between the 48 
hour and 96 hour water wash).  
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Figure 4.7 Reductions in Burst due to IPA Wash Versus Water Wash 
A further study was initiated to find the ideal water wash length that would reduce 
the initial burst to an appropriate level while allowing a reproducible manufacturing 
wash procedure with.  Ocular Inserts in this study were made with 7% API in a 10A 
matrix.  
The washing container used for all previous studies that utilized washing, either with 
IPA or water, was a large glass jar (unless otherwise specified, as for individually washed 
samples). Samples would be placed inside the same jar and the appropriate wash 
medium would be added.  
A Washing Tray, which would segregate all Ocular Inserts during washing, was 
introduced in order to improve the manufacturing flow of the product. A large 
polypropylene washing basin was used to hold the Washing Tray, and the basin was 
then filled with the washing medium. This basin was then stored in a shaking incubator 
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set at 600C and 55 RPM for the duration of the wash. All Inserts were washed and then 
irradiated.  
 
Figure 4.8 Effect of Water Wash Length on Release Rate Using Washing Manufacturing 
Conditions 
The data shown in Figure 4.8 demonstrates that both a 48 and 72 hour water 
wash reduce the initial burst from Ocular Inserts, while still maintaining a long term 
release rate profile comparable to unwashed samples. The 48 hour wash was chosen 
due to ease of manufacturing. 
4.2.3. 20% API/30A Silicone Matrix Studies 
In order to produce a product that could deliver an acceptable dose for 6 months 
rather than 3 months, a higher drug loading of the silicone matrix was attempted. This 
was expected to increase the release rate, but also increase the initial burst of drug 
from the Inserts. Therefore, studies were conducted to find the ideal washing conditions 
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to maintain the increased release rate of drug while keeping the initial drug burst from 
the device in an acceptable range.  
Silicone Segments were made with 20% API loading in the 30A silicone matrix and 
were washed individually in glass vials containing water that were stored inside an oven 
set at 600C for 48 hours. Following the water wash, samples were washed with 70% IPA 
for 15 minutes followed by a 1 minute 70% IPA rinse.  Figure 4.9 shows the data for this 
study, and compares it with data from a previous 7% drug loading study with similar 
washing conditions. 
 
Figure 4.9 20% Drug Load vs. 7% Drug Load Effect of Water Wash on Release Rate 
Comparison 
This study demonstrated that increasing the drug loading from 7% to 20% 
increases the burst as well as the long term release rate profile. The 48 hour wash 
followed by the 70% IPA wash still removes enough of the API so that the initial burst is 
acceptable.  
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Although the studies described above demonstrated that a 20% API loading 
provides a higher release rate profile than a 7% load, and a 48 hour wash is adequate to 
remove the initial burst, additional testing was done to confirm the effect of wash 
length on release rate. 
Ocular Inserts made with 19% API (though deviation from 20% occurred during 
formulation, release rate profiles were deemed equivalent) in a 30A silicone matrix 
were washed individually in plastic jars containing water that were stored inside a 
shaking incubator set at 55 RPM and 600C.  Samples were washed in water for different 
lengths of time (6 hours, 24 hours, and 48 hours), and a 15 minute 70% IPA wash at 
room temperature followed the water wash. 
 
Figure 4.10 Effect of Water Wash Length on Release Rate of 19% API loaded matrix 
As expected, the results demonstrated the correlation between wash length and 
initial release rate (increasing the wash length lowered the initial release rate), as was 
demonstrated by a similar study done with 7% drug loaded samples (see Figure 4.10). 
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The long term release rate was not significantly affected however, as the release profiles 
for all samples began to converge around Day 30.  
The release rate of the 48 hour wash sample was also very similar to the release 
rate seen from the 48 hour washed samples described above, indicating repeatability 
The previous studies utilizing a 20% API loading demonstrated the feasibility of 
using an increased drug loading to increase the long term release rate. The next step 
was to show that the washing process was transferrable to a larger scale ‘manufacturing 
wash’ set-up. 
Ocular Inserts made with 20% API in a 30A silicone matrix were washed in a 
custom Teflon tray that separated all Ocular Inserts. This tray was submerged into a 
polypropylene basin filled with water pre-heated to 600C, and the basin was held inside 
a shaking incubator set at 50 RPM and 600C. The Ocular Inserts were washed for 48 
hours in the shaking incubator. Upon removal, Ocular Inserts were washed with 70% IPA 
for 15 minute at ambient conditions. 
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Figure 4.11 Feasibility of the Manufacturing Washing Configuration for 20% API 
loaded product 
The results shown in Figure 4.11 from the basin wash indicate that using the 
manufacturing washing configuration provided a release profile similar to that seen 
from samples washed individually. To confirm repeatability of the manufacturing wash 
process, 10 additional samples were tested (Figure 4.12).  
 
Figure 4.12 Repeatability of the Manufacturing Conditions  
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Although the repeat samples average release rate profile was slightly higher, the 
basin washed and repeat basin washed samples release rate profiles fell within a 
relative standard deviation of 10%, as displayed in Figure 4.13 below: 
 
Figure 4.13 20% Drug Load, 48 Hour Wash Comparison 
4.2.4. Results and Discussion 
While the 7% load configuration can increase the release rate profile to over 
4 µg/day through 118 days, it also produces a large burst of API. It was found that 
washing Ocular Inserts using 50, 70 or 99% IPA can moderate the burst significantly, 
although washing with 99% IPA had the potential to affect both the initial burst and the 
long term release more than when washing with 50 or 70% IPA. For example, washing 
Ocular Inserts with 50% IPA for 15 minutes can reduce the burst from approximately 
110 µg/day to 68 µg/day, while still maintaining a high release rate profile. Washing 
with 99% IPA also reduces the burst but lowers the overall release profile.  
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Though the day1 burst was reduced to 68 µg/day, it was desired to reduce the burst 
still further. This was accomplished by washing Ocular Inserts in water at high 
temperatures for an extended period of time, followed by a 15 minute 70% IPA wash. 
Washing in water at 600C for 48 hours reduced the burst from approximately 68 µg/day 
to 18 µg/day, while maintaining the long term release rate profile. 
Clinical data suggested that higher dosing was more desirable resulting in a 20% 
loaded product. Through testing, results indicated a long term release rate 
approximately double that of the 7% loading was achievable. Burst moderation was 
achieved with identical water wash parameters used with the 7% loaded product. For 
example, Ocular Inserts washed inside a water filled basin placed inside a shaking 
incubator set at 600C for 48 hours produced a burst well under 60 µg/day while still 
maintaining a release rate profile eluting over 8 µg/day by day 92. 
A previous study had shown that the day 1 drug release burst for 20% API in the 
30A silicone is in the range of 200-300 µg/day, which is well above a desirable level. In 
order to bring the day 1 burst release of the drug to a more acceptable level, the Ocular 
Inserts were washed for different lengths of time in water at 60ºC with continuous 
shaking. The data in Figure 4.14 show that a 10-hour wash brought the burst release of 
drug on day 1 to approximately 70 µg/day, while the 48-hour and 72-hour washes 
brought the day 1 burst release to approximately 30-40 µg/day, an acceptable level. As 
both 48-hr and 72-hr water washes result in satisfactory day 1 burst profiles, the 48-hr 
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wash time was recommended as a good overall balance for product performance and 
manufacturing efficiency. 
 
Figure 4.14 Effect of Water Wash Time on Release Rate of 20% API loaded product 
4.3. Manufacturing Reproducibility  
The 20% API in a 30A silicone formulation has been prepared multiple times 
using the same lot of drug substance and different lots of silicone to evaluate batch to 
batch reproducibility.  The data in Figure 4.15 show that three different batches of 
Ocular Inserts manufactured with the recommended 48-hr water wash followed by 15-
min 70% IPA rinse provide very similar release rate profiles 
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Figure 4.15 Reproducibility for Three Different Batches 
A 20% API in a 30A silicone formulation has been successfully developed. The 
formulation together with an appropriate manufacturing process has achieved 
acceptable assay and impurity levels, and desirable drug release profile. A water wash at 
60°C for 48 hours incorporated into the manufacturing process prior to pouching has 
been found to bring down the Day 1 initial burst to a desirable level. A reproducible drug 
release profile has been demonstrated for at least three consecutive development 
batches. 
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5. Understanding the Mechanisms of Release 
 
5.1. Purpose 
Mathematical modeling of the release rate of materials from polymer matrices is 
of particular interest to formulation chemists. One of the goal when developing any 
medical device is to develop the ability to control the properties of any system. Control 
of the formulation allows for optimization of the product; optimization allows for a 
tighter parameters during the manufacturability of the product.  If the release rate of 
the device can be accurately predicted, it would show a certain degree of control over 
the system.  
5.2. Controlled Release of Diffusion Based Processes 
Diffusion is the transport of small molecules by random molecular motion of 
individual molecules from an area of high concentration to low concentration. Figure 5.1 
below shows a typical schematic of this phenomenon analogous to the system 
developed by ForSight Labs.  Diffusion is a spontaneous process; it increases entropy, 
decreases Gibbs free energy, and is therefore isothermal dynamically favorably. 
 
Figure 5.1 Drug Release Mechanism Analogous to System Developed At ForSight 
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There are several factors that contribute to the transport process including the 
nature of the polymer, nature of cross links, effect of plasticizers, nature of penetrants, 
presence of fillers, effect of temperature, and presence of other variables that may be 
included in the system. The nature of the polymer includes the extent of unsaturation, 
degree of crystallinity, and the nature of substituents.  
Different degrees of crosslinking density of the same polymer results in different 
physical properties such as glass transition temperatures (Tg). An increase in diffusion 
coefficient is seen with decreasing Tg (George, 2001). Diffusivity has been shown to 
decrease linearly with an increase in crosslink density until a maximum degree of 
crosslinking is reached resulting in a leveling off effect of diffusivity (Barrer, 1948).   For 
the same polymer with the same crosslink density, diffusion depends on the nature of 
crosslinks. In addition different solvent solutions of drug release affect the release rate 
differently. For example, benzene solutions swell more than corresponding bulk 
crosslinked networks having the same crosslink density which would decrease the rate 
of diffusivity (George, 2001). 
Additional factors that contribute to transport processes are still significant, but 
fall outside the scope of the variables affecting the drug polymer matrix discussed in this 
report. For example, addition of plasticizers to a polymer results in an increased 
segmental mobility which in turn usually increases penetrant transport, e.g. in the 
presence of solvents (George, 2001). The nature of the penetrant determines the 
degree to which the molecule diffuses from the polymer matrix. Fillers and temperature 
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effects may increase or decrease the diffusivity of the molecule as well. The effects of all 
these variables that affect the release rate are captured mathematically in the diffusion 
coefficient of the model. The larger the diffusion coefficient, the higher the rate of 
release. 
The aim of this project was to establish an understanding of the mechanisms 
relating solubility and transport in the polymer membrane to their molecular properties. 
The initial driving factor of the silicone-matrix drug delivery system developed at 
ForSight is diffusion.  However, as at some point in time, the mechanism of diffusion is 
overcome by the formation of channels due to the saturation of the matrix by the API. 
The kinetic model intends to develop a quantitative mechanism for determining the 
diffusion of API from the silicone matrix as well as the potential formation of a channel 
guided release mechanism. 
The development of the model was necessitated by a need to interpret the 
response of release rate. The model was developed at a time when the focus of 
research and development was to optimize the washing parameters in order to 
determine the desired release rate profile. The main issue with release rate 
determination was that it was limited to empirically derived real time data. Since the 
goal was to achieve a sustained release of API over many months, this became the main 
bottleneck of R&D. As the amount of data grew, a need to understand how changes in 
the wash would affect the overall release profile was necessary and resulted in the 
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development of the predictive model. This model minimized the time needed to 
understand the results. 
The objectives of designing a model for controlled drug delivery systems are to:  
1. Optimize the release rate development process 
2. Elucidate the physical mechanisms of drug transport 
3. Aid in the design new drug delivery systems based on release expressions 
4. Predict drug release rates from and drug diffusion behavior through polymers 
The purpose of mathematical models is to ultimately help optimize the design of a 
therapeutic device to yield information on the performance of the device as well as 
show the degree of accuracy through predictive models, thus avoiding excessive 
experimentation 
 
Figure 5.2 Release Rate Profiles of 7% and 20% Drug Loading Used for Modeling 
Release rate profiles as seen in Figure 5.2 are broken down into several sections 
when applied for mathematical modeling. Release kinetics follow a well-defined 
behavior: first a rapid initial release (termed the “burst”) followed by a slow near-zero 
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order release rate.  The goal is to develop a model that both accurately models and has 
the capability of predictively determines release data.  
5.3. A Background of Mathematical Modeling  
5.3.1. Fick’s Law and its Analogous Counterparts 
Adolf Fick was able to empirically derive an equation for diffusion in 1855. 
Inspired by many prominent scientists of his day, Fick’s laws of diffusion are analogous 
to the laws of transport and flow developed by Darcy (flow of liquid through a porous 
medium), Ohm (flow of current through two points) and Fourier (flow of heat). Their 
respective fundamental laws are described below.  
Adolf Fick was the first to propose laws that govern the transport of mass 
through diffusive means. In addition to inspiration indirectly drawn from Ohm, Fourier, 
and Darcy, Fick was directly inspired by earlier experiments in diffusion by Thomas 
Graham. Although Thomas Graham was unsuccessful in his efforts, Fick was able to 
further Graham’s understanding and arrived at his successful laws of diffusion. 
Fick’s experiments dealt with measuring the concentrations and fluxes of salt 
diffusing between two reservoirs through tubes of water. His laws were primarily 
concerned with diffusion in fluids, because diffusion in solids was not considered 
possible at the time. Today, Fick’s laws form the core of our understanding of diffusion 
in solids, liquids, and gases in the absence of bulk fluid motion (for liquids and gases). 
When a process does not follow Fick’s laws, we refer to the process as non-Fickian. 
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Though Fick is credited with development of the understanding of the 
phenomena of diffusion, the evaluation of diffusion of solids was modeled by Noyes and 
Whitney in 1897 with the following equation: 
𝑑𝑀
𝑑𝑡
= 𝐾𝑆 (𝐶𝑠 −  𝐶𝑡) 
where M is the mass transferred over time, t, by dissolution from the solid particle over 
a surface, S, under the driving force of the concentration difference (Cs – Ct) where Ct is 
the concentration at time t and Cs is the equilibrium solubility of the solute at the 
experimental temperature. The rate of dissolution dM/dt is the amount dissolved per 
unit area per unit time and can generally be expressed in units g∙cm-2∙s-1.  
To better fit more complicated systems, these fundamental models have been 
manipulated by the incorporation of appropriate variables. Additionally, the 
development of these models has allowed for their application in other systems. For 
example, the diffusion mechanism which was first explained by Fick has since been 
modified by many scientists over the years into workable formulas for explaining the 
diffusion of pharmaceuticals. Though these models give credence to the Fick, they have 
been aptly renamed and are specific for their own systems. The proceeding sections 
gives insight into these models which have been applied to drug release from matrices. 
5.3.2. Higuchi Model 
The first model aimed to describe drug release from a matrix system was 
developed by Higuchi in 1961. Initially developed for planar systems, it was later 
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developed into applications that incorporated multiple geometries and porosities. 
Several assumptions made by Higuchi include: 
i. Initial drug concentration in the matrix is much higher than drug solubility; 
ii. Drug diffusion takes place only in one dimension (“edge effect must be 
negligible”); 
iii. Drug particles are much smaller than the channels through which they travel; 
iv. Matrix swelling and dissolution are negligible; 
v. Drug diffusivity is constant; 
vi. Perfect sink conditions are always attained in the release environment. 
These same assumptions are the basis for the other mathematical models discussed in 
this report. 
The basic model described by Higuchi is expressed by the equation: 
𝑓𝑡 = 𝑄 = 𝐴√𝐷(2𝐶 − 𝐶𝑠)𝐶𝑠𝐶𝑡 
where ft  is the cumulative fraction of drug in a given area at time t, Q is the amount of 
drug released in time t per unit area A, C is the initial drug concentration, Cs is the drug 
solubility in the matrix media and D is the diffusion coefficient in the matrix substance. 
The fundamental understanding of application of models on release kinetics was 
effectively established by Higuchi. Future model developers typically have their 
foundation in principles that Higuchi established (Dash, 2012). 
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5.3.3. Korsmeyer-Peppas Model (The Power Law)  
In an effort to develop a more versatile kinetic model, Korsmeyer-Peppas proposed 
a model based on empirically derived data to describe drug release from polymeric 
systems in 1983 (Korsmeyer et al 1983): 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛  
where Mt/M∞ is a unit less cumulative fraction of drug released at time t, k is the 
release rate constant and n is the release exponent. While modifications of the 
Korsmeyer-Peppas model enables its application to various geometries, it is principally 
due to the position and simplicity of the n-variable that the model is typically applied to 
cylindrical shaped matrices when found in the most basic form.Depending on the value 
of the n-variable, the characteristics of the polymer matrix can be elucidated. A value of 
n= 0.5 indicates a Fickian diffusion drug transport mechanism. For cylindrical matrices, a 
value of n ≤ 0.45 is the most commonly found. A value of 0.45<n<0.89 corresponds to 
non-Fickian transport, n=0.89 for Case II relaxational transport, and n>0.89 for super 
relaxational transport. To determine the exponent n, drug release data in the initial 
range of Mt/M∞ < 0.6 are used to simulate the release profile. Release kinetics modeled 
under the Korsmeyer-Peppas method are best plotted as log cumulative percentage 
drug release versus log time (Dash 2012). 
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Table 5.1 Interpretation of Diffusional Release Mechanisms from Polymeric Films 
Release Exponent (n) Drug Transport Mechanism Rate as a Function of Time 
0.5 Fickian diffusion t-0.5 
0.45<n=0.89 Non-Fickian transport tn-1 
0.89 Case II transport Zero Order Release 
Higher than 0.89 Super case II transport tn-1 
 
5.3.4. Hixon-Crowell Model 
In 1931, Hixson and Crowell recognized that a particle’s “regular” area is 
proportional to the cube root of its volume represented by the equation: 
 𝑊0
1/3
− 𝑊𝑡
1/3
= 𝜅𝑡 
where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the 
remaining amount of drug in the pharmaceutical dosage form at time t and κ is a 
constant which incorporates the surface-volume relation. 
This model is most useful in systems where there is a change in surface area and 
diameter of the pharmaceutical, such as in tablets. When this model is applied, release 
kinetics are typically viewed by plotting the cube root of drug percentage remaining in 
the matrix versus time. The model assumes that the diminishing dimensions of the 
pharmaceutical remain relative to each other (Dash 2012). 
5.3.5. Weibull Model 
Weibull’s model is loosely based off the Weibull distribution discovered in 1951 
to describe a particle size distribution. The Weibull distribution is a probability density 
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function which was empirically derived and which has been adapted to the 
dissolution/release process. 
The equation used when applying the Weibull model follows the form: 
𝑀 = 𝑀0  [1 − (𝑒)
(𝑡−𝑇)𝑏
𝑎 ] 
where M is the amount of drug dissolved as a function of time t, M0 is the total amount 
of drug being released, T accounts for the lag time measured as a result of the 
dissolution process, a denotes a scale parameter that describes the time dependence, 
while b describes the shape of the dissolution curve progression. For b=1, the shape of 
the curve corresponds exactly to the shape of an exponential profile with the constant 
k=1/a resulting in the equation: 
𝑀 = 𝑀0 [(1 − 𝑒)
−𝑘(𝑡−𝑇)] 
The shape of the curve becomes sigmoidal for values of b >1.  
One application of the Weibull model is to determine the time when 50% (w/w) 
and 90% (w/w) of drug released from the formula is achieved: 
𝑡(50% 𝑜𝑟 90%)  =  [−𝑎 𝑙𝑛
𝑀0 − 𝑀
𝑀0
)
1
𝑏 + 𝑇] 
This application allows for comparison of release profiles of pharmaceuticals for product 
development (Dash 2012). 
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5.3.6. Baker-Lonsdale Model 
This model was first developed by Baker and Lonsdale in 1974 from the Higuchi 
model and was used to describe drug release from spherical matrices such as 
microcapsules or microspheres. The generic equation of the model follows:  
𝑓1 =  
3
2
[1 − (1 −
𝑀𝑡
𝑀∞
)2/3]
𝑀𝑡
𝑀∞
= 𝑘𝑡 
where k corresponds to the slope. Release kinetic data is most readily applied to 
linearized data in the form [d(Mt/M∞  )]/dt with respect to the root of time inverse (Dash 
2012). 
5.3.7. Selection of an Appropriate Model  
The most commonly applied models used to describe release phenomena are the 
Higuchi model, the Zero order model, the Weibull model, and the Korsmeyer-Peppas 
model. A summary of mathematical models can be seen in Table 5.2.   
Table 5.2 Mathematical Models Used to Describe Drug Dissolution Curves. 
Zero Order Qt  = Qo + Kot 
First Order lnQt  = lnQo + K1t 
Second Order Qt/Q∞(Q∞--Qt ) Qo + Kot 
Hixson-Crowell Qo1/3  - Qt1/3 =K1t 
Weibull log[-ln(1-(Qt/Q∞))] = b X log t – log a 
Higuchi Qt =KH√t 
Baker-Lonsdale (3/2)[1-(-1(Qt/Q∞))2/3] – (Qt/Q∞) = Kt 
KorsMeyer-Peppas Qt/Q∞  = Kk tn 
Selection of an appropriate model can be quantified using the coefficient of 
determination, R2, which gives an appropriate fit of the model. For the determined 
models, the fit of the model was calculated using: 
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𝑅2 =
𝑆𝑆𝑅
𝑆𝑆𝑇
=  
𝑆𝑆𝑅
𝑆𝑆𝑅 + 𝑆𝑆𝐸
 
SSR is the sum of squares due to regression determined by SSR = Σ(Ŷ-Ymean )2 . SSE is the 
sum of squares due to error determined by SSE = Σ(Y-Ŷ)2 . SST is the total sum of 
squares. Depicted in Figure 5.3, Ŷ is the predicted value for each Y. Since regressions are 
not exact fittings, there usually is some difference between each Y value and the fitted Y 
value. Ymean is the average of all empirically derived Y values.  
 
Figure 5.3 Diagram for Determining Y-Values. 
5.4. Model of 7% Drug Loading Washed in 70% IPA for 15min 
5.4.1. Development of a Model 
The Korsmeyer-Peppas model was chosen for developed drug-polymer matrix 
developed due to its ease of application and robustness when applied to cylindrical 
matrices. At ForSight, derived data was reported as release rate over a predetermined 
interval of analysis (Day 1, 2, 4, 7, 14, 21, 28, 58, 88, 118, 148, 178). The release rate 
data tended to result a higher value of the actual release rate due to it inherently taking 
a running average of the data. For example, when sampling a release rate at a 30-day 
interval, the value tended to be higher since it involved taking a moving average of the 
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previous 30-days. In order to more accurately view the data, a necessary conversion to 
cumulative amount was needed.  
5.4.2. Results and Discussion 
In order to convert the release rate data to cumulative release, an accurate 
measure of the total drug content was needed. The assay data in Table 5.3 shows an 
average device weight in mg and amount of drug in micrograms and was obtained using 
the Content Uniformity and Assay and Impurities determination outlined in Section 3.1 
of this report. An average recovery through HPLC analysis tended to yield 97% and was 
used as a conversion factor to aid modeling. Resulting data is shown in Tables 5.3 and 
5.4. 
Table 5.3 Assay Data From 7% Drug Loaded Device 
Wash Method 
Device Weight  
(mg) 
Amount of Drug in Device 
(µg) 
97% 
recovery 
70% IPA for 15min 64.372mg 4506.04 4370.86µg 
Applying the assay data to the release rate yields the cumulative fraction of drug 
through the following equation: 
𝑅𝑒𝑙𝑒𝑎𝑠𝑒 𝑅𝑎𝑡𝑒2 − 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 𝑅𝑎𝑡𝑒1  
𝑇𝑖𝑚𝑒 𝑃𝑜𝑖𝑛𝑡2 −  𝑇𝑖𝑚𝑒 𝑃𝑜𝑖𝑛𝑡1
 ÷ 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑟𝑢𝑔 𝑖𝑛 𝐷𝑒𝑣𝑖𝑐𝑒 
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Table 5.4 Release Rate Data of 7% Device and Converted Cumulative Amounts 
Day 
Release Rate 
(µg/day) 
Cumulative 
(µg) Cumulative Fraction 
1 59.8 59.8 0.01 
2 34.6 94.4 0.02 
4 24.7 143.72 0.03 
7 19.1 201.08 0.05 
14 13.42 295.02 0.07 
21 10.0 364.74 0.08 
29 8.2 430.02 0.10 
57 5.0 570.02 0.13 
88 4.5 710.76 0.16 
118 3.8 824.16 0.19 
148 3.7 935.16 0.21 
 
 
Figure 5.4 Cumulative Release Model Predicted Fit Versus Experimental of 7% Drug 
Loading Washed in 70% IPA for 15min 
 
Application of a power regression fit according to Fick’s law from the total 
available data and results for the Day 1-148 fit are seen in Figure 5.4. The modeled 
cumulative release fit is used to back calculate the release rate shown in Figure 5.5. 
While the model is a good fit relative to the real data upon initial view, discrepancies in 
release rate can be seen with the model resulting in a slightly higher predicted release 
rate. 
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Figure 5.5 Release Rate: Model Developed Versus Experimental of 7% Drug Loading 
Washed in 70% IPA for 15min 
The full data model fit in Figures 5.4 and 5.5 show how closely the 
experimentally derived data follows power law functions and allowed for accurate use 
for predictive modeling. Because of the availability of data through day 148, predictive 
models could be instantly measured against real experimental data before being applied 
to new systems. Figure 5.6 shows the progression of the model as more time points 
became available relative to the empirical data. 
 
Figure 5.6 Cumulative Release: Prediction Intervals Versus Experimental of 7% Drug 
Loading Washed in 70% IPA for 15min. 
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Predictive models utilized a maximum of data through Day 28 since the majority 
of the release rate burst was diminished by this point and tended to show a near zero-
order release rate past this point. Additionally, sampling time points were taken at Day 
1, 2, 4, 7, 14, 21, and 28. Past Day 28, sampling time points were taken every 30 days. 
The time cost was greater than the marginal increase in model accuracy.  
  The predicted cumulative fractions were roughly 5% above the modeled fit by 
Day 150, the resulting release rate predictions were within 3µg for the Day 7 model and 
1 µg for the Day 28 model. Since this difference was deemed within acceptable limits, 
the model was applied to other different wash conditions with different release rate 
profiles. 
 
Figure 5.7 Release Rate: Prediction Intervals Versus Experimental of 7% Drug Loading 
Washed in 70% IPA for 15min 
Graphically represented in Figure 5.7, a measurement of the fit of the models is 
tracked through analyzing their R2  values as summarized in Table 5.5. The Predictive 
models result in a higher degree of accuracy than the full modeled fit and the Fickian Fit, 
though all fits are above 95% accurate. As the model utilized more data points, the 
59 
 
predicted fit approaches a 99% coefficient of determination. Calculation of the goodness 
measure of fit can be found in Appendix A.  
Table 5.5 Measure of Fit of Model Based on Amount of Data 
Data Range Model 
R2 
of Release 
Rate Model 
vs Empirical 
Data 
Days 1-7 y = 0.0138x0.6219 0.976 
Days 1-14 y = 0.014x0.6048 0.984 
Days 1-21 y = 0.0141x0.593 0.986 
Days 1-29 y = 0.0143x0.584 0.987 
Days 1-148 y = 0.0152x0.538 0.976 
Fickian Fit y = 0.0168x0.5 0.950 
5.5. Model of 20% Drug Loading Washed in Water for 48hours at 60˚C 
5.5.1. Development of a Model 
The 20% Drug/Silicone matrix presented significant challenges. By increasing the 
drug loading in the polymer matrix, the characteristic behavior of the silicone was 
significantly changed. Previously, the 7% loaded device behaved under near ideal 
diffusion based mechanisms. However, the 20% loaded matrix showed signs of a change 
in the mechanism of release due to the increase in drug loading. This change in the 
matrix was signaled during formulation developments where the 10A silicone was 
incapable of incorporating the higher drug load without affecting the physical properties 
of the silicone and required an alternative silicone in order to maintain structural 
properties post curing.  In addition, the nonlinear increase in release rate that occurred 
between 10% and 15% drug loading indicated that a new mechanism of release may 
exist. 
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5.5.2. Results and Discussion 
Table 5.6 Assay Data From 20% Drug Loaded Device 
Wash 
Device Weight 
(mg) 
Amount Drug 
(µg) 
48hrs @ 60oC 70.56 12132.0 
 
After wash, the amount of drug in each insert averaged 12mg (Table 5.6). The 
resulting release rate was once again converted to cumulative fractions shown in Table 
5.7. 
Table 5.7 Release Rate and Cumulative Release Data from 20% Drug Loading   
Day 
Release Rate 
(µg/day) 
Cumulative 
(µg) 
Cumulative 
Fraction 
1 36.68 36.68 0.003 
2 24.42 61.11 0.005 
4 22.06 105.22 0.009 
7 21.21 168.86 0.014 
14 18.01 294.95 0.024 
22 15.18 416.37 0.034 
28 13.93 499.95 0.041 
60 11.35 863.25 0.071 
91 9.54 1158.99 0.096 
120 8.05 1275.77 0.105 
150 6.86 1378.70 0.114 
The final product had a significant drug load increase from 7% to 20% and was 
washed at 48hours at 60oC. The application of the normal model fit showed a cross 
between the experimental data and the regression model fit between at Day90 (Figure 
5.8). 
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Figure 5.8 Cumulative Release Model Predicted Fit Versus Experimental of 20% Loading 
Washed in Water for 48hours at 60˚C 
While the intersection was present when viewing the data as a cumulative 
fraction at Day 90, the only intersection for the release rate view was at Day 30 (Figure 
5.9). This overlap was investigated and theorized as one of the main reasons for the 
differences caused between experimentally derived and modeled data.  
 
Figure 5.9: Release Rate Model Developed Versus Experimental of 20% Loading Washed 
in Water for 48hours at 60˚C 
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The resulting predictive models deviated from experimental data by ~5% by Day 
150 (Figure 5.14). This inaccuracy was investigated and attributed to a change in the 
release rate mechanism of the device that was not observed with the 7% loading.  
 
 
Figure 5.10 Cumulative Release Model Predicted Fit Versus Experimental of 20% Loading 
Washed in Water for 48hours at 60˚C 
 
The cumulative release view of data tended to highlight discrepancies. Resulting 
in a ~4µg difference between empirical and predicted data by Day 150 (Figure 5.15). 
 
 
Figure 5.11 Release Rate: Prediction Intervals Versus Experimental of 20% Loading 
Washed in Water for 48hours at 60˚C 
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The resulting release kinetics fit of the 20% modeled fit with 48 hour wash at 
60oC showed a roughly ~95% goodness of fit (Table 5.11). Calculation of the goodness 
measure of fit can be found in Appendix C. 
Table 5.11 Measure of Fit of Model Based on Variable Amounts of Data 
Data Range Model 
R2 
of Release Rate 
Model vs 
Empirical Data 
Days 1-7 y = 0.003x0.7835 0.963 
Days 1-14 y = 0.003x0.7935 0.942 
Days 1-21 y = 0.003x0.7933 0.942 
Days 1-28 y = 0.003x0.7919 0.946 
Days 1-150 y = 0.0032x0.7449 0.973 
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6. Conclusions 
Application of a direct Korsmeyer-Peppas fit as a prediction model resulted in a 
less than ideal fit of the actual release rates. During release rate determinations, it can 
be seen that regardless of the range of data used to forecast a predicted release rate, 
the predicted release rate values are significantly higher than the experimental values.  
The first generation model involved fitting the known Korsmeyers-Peppas model. 
However an iteration of the model was necessary in order to achieve a higher degree of 
accuracy. Initially, this modification of the model was not necessary for the 7% Loading 
since application of the basic Korsmeyers-Peppas model showed a high degree of 
accuracy. For the higher 20% drug loading, a need for modification of the model was 
necessary, due to several competing theories as to why the power law fit no longer 
sufficed. 
The release profile of this insert is over 180 days. This extended length of time 
was not something that Korsmeyer’s Peppas likely accounted for when they developed 
their initial model. The power law fit is ideal when the cumulative release fraction is 
<0.6. Even after 180 days, the 20% loaded insert only showed <15% of total drug 
released. This slow release is due to the low diffusion coefficient of drug in the silicone 
matrix. In addition, the power fit is best for Fickian diffusion based mechanisms of 
release. While this mechanism held true with 7% drug loading, the 20% drug loading 
showed a power coefficient that indicated both Fickian diffusion and a non-Fickian 
mode of transport as the mechanism of release.  This dual mechanism may change over 
65 
 
time resulting in a different contribution of each mechanism during different periods of 
time. For example, the release mechanism may initially have been purely due to Fickian 
diffusion. As drug diffused over time, channels were formed within the polymer matrix. 
The mechanism of channel formation in this case is analogous to non-Fickian transport 
since Fickian diffusion is based on “random walk” of molecules. When enough drug was 
removed from the surface, the main mode of release was through the channels, 
resulting in a need to modify the power law fit in order to account for the mechanism 
changes. While The Korsmeyer-Peppas fit was ~95% accurate there was room to 
improve resulting in a second generation model.  
This second generation model was a mixture of two models based off of the 
power law. The first model included the burst and the initial release time points. The 
second model took into account the later release profile. The final model was an 
average of the two models and resulted in higher degree of accuracy. While the model is 
still in development, the initial developments are shown in Appendix D.  
Process optimization was achieved by the development of a model. Reduction in 
R&D time constraints significantly reduced the real-time nature of data release.  
Model developments in the future may be able to incorporate temperature, drug 
loading, and solution system variables. While it has proven difficult to correlate a 
dependence from one system to the next (i.e. 37⁰C  60⁰C, 7% loading  20%, or PBS 
media to IPA), the developed model has the potential to be accurate in predicting the 
outcomes while keeping those aforementioned variables constant. 
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Appendix A 
7% Drug Loading, 15min 70% IPA Wash 
Predictive Model Day 1-7 
y = 0.0138x0.6219 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate SSR SSR SSE SSE 
1 0.01 0.00 60.32 0.52 43.32 
1876.4
4 -0.50 0.27 
2 0.02 0.00 32.51 -2.09 15.51 240.42 2.10 4.39 
4 0.03 0.00 25.01 0.31 8.01 64.18 -0.30 0.10 
7 0.05 0.00 19.82 0.72 2.82 7.96 -0.70 0.52 
14 0.07 0.00 15.57 2.15 -1.43 2.03 -2.20 4.64 
21 0.09 0.01 12.76 2.76 -4.24 18.01 -2.80 7.59 
29 0.11 0.01 11.13 2.93 -5.87 34.43 -2.90 8.60 
57 0.17 0.04 9.14 4.14 -7.86 61.86 -4.10 17.10 
88 0.22 0.06 7.46 2.96 -9.54 91.08 -3.00 8.74 
118 0.27 0.08 6.52 2.72 -10.48 109.93 -2.70 7.37 
148 0.31 0.09 5.91 2.21 -11.09 122.98 -2.20 4.89 
Sum   0.03  19.31 19.13 
2629.3
2  64.20 
 
Predictive Model Day 1-14 
y = 0.014x0.6048 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate SSR SSR SSE SSE 
1 0.01 0.00 61.19 1.39 44.19 
1952.9
4 -1.40 1.94 
2 0.02 0.00 31.87 -2.73 14.87 221.02 2.70 7.47 
4 0.03 0.00 24.23 -0.47 7.23 52.29 0.50 0.22 
7 0.05 0.00 19.00 -0.10 2.00 4.00 0.10 0.01 
14 0.07 0.00 14.77 1.35 -2.23 4.98 -1.30 1.82 
21 0.09 0.00 11.99 1.99 -5.01 25.14 -2.00 3.94 
29 0.11 0.01 10.40 2.20 -6.60 43.61 -2.20 4.82 
57 0.16 0.03 8.46 3.46 -8.54 73.00 -3.50 11.94 
88 0.21 0.05 6.84 2.34 -10.16 103.26 -2.30 5.47 
118 0.25 0.06 5.94 2.14 -11.06 122.35 -2.10 4.57 
148 0.29 0.07 5.36 1.66 -11.64 135.40 -1.70 2.77 
Sum   0.02  174.73 13.04 
2737.9
9  44.98 
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Predictive Model Day 1-21 
y = 0.0141x0.593 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate 
SSR SSR SSE SSE 
1 0.01 0.00 61.63 1.83 44.63 1991.76 -1.80 3.35 
2 0.02 0.00 31.33 -3.27 14.33 205.38 3.30 10.69 
4 0.03 0.00 23.63 -1.07 6.63 43.95 1.10 1.15 
7 0.04 0.00 18.39 -0.71 1.39 1.94 0.70 0.50 
14 0.07 0.00 14.19 0.77 -2.81 7.89 -0.80 0.59 
21 0.09 0.00 11.44 1.44 -5.56 30.86 -1.40 2.09 
29 0.10 0.01 9.88 1.68 -7.12 50.63 -1.70 2.84 
57 0.16 0.02 7.99 2.99 -9.01 81.17 -3.00 8.95 
88 0.20 0.04 6.42 1.92 -10.58 111.91 -1.90 3.69 
118 0.24 0.05 5.55 1.75 -11.45 131.04 -1.80 3.07 
148 0.27 0.06 5.00 1.30 -12.00 144.00 -1.30 1.69 
Sum   0.02  74.80 8.47 2800.53  38.59 
 
Predictive Model Day 1-29 
y = 0.0143x0.584 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate 
SSR SSR SSE SSE 
1 0.01 0.00 62.50 2.70 45.50 2070.55 -2.70 7.31 
2 0.02 0.00 31.19 -3.41 14.19 201.33 3.40 11.63 
4 0.03 0.00 23.38 -1.32 6.38 40.66 1.30 1.75 
7 0.04 0.00 18.10 -1.00 1.10 1.20 1.00 1.01 
14 0.07 0.00 13.88 0.46 -3.12 9.72 -0.50 0.21 
21 0.08 0.00 11.14 1.14 -5.86 34.32 -1.10 1.30 
29 0.10 0.00 9.59 1.39 -7.41 54.89 -1.40 1.94 
57 0.15 0.02 7.72 2.72 -9.28 86.16 -2.70 7.39 
88 0.20 0.03 6.17 1.67 -10.83 117.25 -1.70 2.79 
118 0.23 0.04 5.32 1.52 -11.68 136.43 -1.50 2.31 
148 0.26 0.05 4.78 1.08 -12.22 149.35 -1.10 1.16 
Sum   0.00  48.27 6.77 2901.87  38.81 
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Day 1-148 Fit 
y = 0.0152x0.538 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate 
SSR SSR SSE SSE 
1 0.02 0.00 66.44 6.64 49.44 2444.02 -6.60 44.05 
2 0.02 0.00 30.03 -4.57 13.03 169.70 4.60 20.91 
4 0.03 0.00 21.80 -2.90 4.80 23.03 2.90 8.42 
7 0.04 0.00 16.40 -2.70 -0.60 0.36 2.70 7.28 
14 0.06 0.00 12.22 -1.20 -4.78 22.85 1.20 1.44 
21 0.08 -0.01 9.57 -0.43 -7.43 55.21 0.40 0.19 
29 0.09 -0.01 8.10 -0.10 -8.90 79.17 0.10 0.01 
57 0.13 0.00 6.37 1.37 -10.63 113.06 -1.40 1.87 
88 0.17 0.01 4.97 0.47 -12.03 144.82 -0.50 0.22 
118 0.20 0.01 4.21 0.41 -12.79 163.58 -0.40 0.17 
148 0.22 0.01 3.74 0.04 -13.26 175.89 0.00 0.00 
Sum   0    3391.69  84.55 
 
Fickian Fit 
y = 0.0168x0.5 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Cumulative 
Predicted 
Release Rate 
Difference From 
Real Release Rate 
SSR SSR SSE SSE 
1 0.02 0.00 73.43 13.63 56.43 
3184.3
9 -13.60 185.79 
2 0.02 0.00 31.03 -3.57 14.03 196.95 -31.00 962.25 
4 0.03 0.00 21.64 -3.06 4.64 21.49 -21.60 467.17 
7 0.04 0.00 15.90 -3.20 -1.10 1.21 -15.90 251.77 
14 0.06 0.00 11.56 -1.86 -5.44 29.54 -11.50 132.67 
21 0.08 -0.01 8.87 -1.13 -8.13 66.04 -8.80 77.49 
29 0.09 -0.01 7.41 -0.79 -9.59 91.96 -7.30 53.57 
57 0.13 0.00 5.71 0.71 -11.29 127.45 -5.60 31.34 
88 0.16 0.00 4.36 -0.14 -12.64 159.70 -4.20 17.58 
118 0.18 0.00 3.65 -0.15 -13.35 178.25 -3.40 11.73 
148 0.21 -0.01 3.21 -0.49 -13.79 190.23 -2.90 8.64 
Sum   0.00  0.00  
4247.2
0  
2200.0
0 
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Appendix B 
20% Drug Loading, 48hours 60oC Wash 
Predictive Model Day 1-7 
y = 0.003x0.7835 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Experimental 
Cumulative 
Predicted 
Release Rate 
Difference From 
Experimental 
Release Rate SSR SSR SSE SSE 
1 0.00 0.00 36.40 -0.28 19.37 375.04 0.28 0.08 
2 0.01 0.00 26.25 1.83 9.22 85.05 -1.83 3.36 
4 0.01 0.00 22.59 0.53 5.56 30.96 -0.53 0.29 
7 0.01 0.00 19.78 -1.43 2.75 7.57 1.43 2.04 
14 0.02 0.00 17.23 -0.78 0.20 0.04 0.78 0.61 
22 0.03 0.00 15.29 0.11 -1.74 3.04 -0.11 0.01 
28 0.04 0.00 14.21 0.28 -2.82 7.93 -0.28 0.08 
60 0.07 0.00 12.65 1.30 -4.39 19.23 -1.30 1.68 
91 0.10 0.01 11.20 1.66 -5.83 33.95 -1.66 2.77 
120 0.13 0.02 10.41 2.36 -6.62 43.83 -2.36 5.57 
150 0.15 0.04 9.87 3.01 -7.17 51.33 -3.01 9.03 
Average:  0.01  0.78  657.99  25.51 
 
Predictive Model Day 1-14 
y = 0.003x0.7935 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Experimental 
Cumulative 
Predicted 
Release Rate 
Difference From 
Experimental 
Release Rate 
SSR SSR SSE SSE 
1 0.00 -26.25 36.40 -0.28 19.37 375.04 0.28 0.08 
2 0.01 -22.59 26.69 2.27 9.66 93.28 -2.27 5.14 
4 0.01 -19.77 23.13 1.07 6.10 37.20 -1.07 1.14 
7 0.01 -17.21 20.38 -0.84 3.35 11.19 0.84 0.70 
14 0.02 -15.26 17.86 -0.15 0.83 0.68 0.15 0.02 
22 0.04 -14.18 15.93 0.75 -1.10 1.20 -0.75 0.57 
28 0.04 -12.60 14.87 0.94 -2.16 4.68 -0.94 0.88 
60 0.08 -11.13 13.30 1.95 -3.73 13.94 -1.95 3.79 
91 0.11 -10.30 11.85 2.31 -5.18 26.87 -2.31 5.32 
120 0.13 -9.73 11.04 2.99 -5.99 35.83 -2.99 8.97 
150 0.16 0.16 10.49 3.63 -6.54 42.73 -3.63 13.20 
Average:  -14.44  1.33  642.65  39.80 
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Predictive Model Day 1-21 
y = 0.003x0.7933 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Experimental 
Cumulative 
Predicted 
Release Rate 
Difference From 
Experimental 
Release Rate 
SSR SSR SSE SSE 
1 0.00 0.00 36.40 11.98 19.37 375.04 0.28 0.08 
2 0.01 0.00 26.68 4.62 9.65 93.11 -2.26 5.11 
4 0.01 -0.01 23.12 1.91 6.09 37.07 -1.06 1.12 
7 0.01 -0.01 20.36 2.35 3.33 11.11 0.85 0.72 
14 0.02 -0.01 17.84 2.66 0.81 0.66 0.17 0.03 
22 0.04 -0.01 15.92 1.99 -1.11 1.23 -0.74 0.55 
28 0.04 -0.03 14.85 3.50 -2.18 4.74 -0.92 0.85 
60 0.08 -0.02 13.28 3.74 -3.75 14.04 -1.93 3.74 
91 0.11 0.00 11.83 3.78 -5.20 27.01 -2.29 5.26 
120 0.13 0.02 11.03 4.17 -6.00 35.98 -2.98 8.89 
150 0.16 0.16 10.48 -6.55 -6.55 42.90 -3.62 13.11 
Average:  0.01  3.11  642.90  39.44 
 
Predictive Model Day 1-28 
y = 0.003x0.7919 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Experimental 
Cumulative 
Predicted 
Release 
Rate 
Difference 
From 
Experimental 
Release Rate 
SSR SSR SSE SSE 
1 0.00 0.00 36.40 11.98 19.37 375.04 0.28 0.08 
2 0.01 0.00 26.62 4.56 9.59 91.94 -2.20 4.83 
4 0.01 -0.01 23.04 1.83 6.01 36.15 -0.98 0.97 
7 0.01 -0.01 20.28 2.27 3.25 10.55 0.93 0.87 
14 0.02 -0.01 17.76 2.58 0.73 0.53 0.26 0.07 
22 0.04 -0.01 15.83 1.90 -1.20 1.45 -0.65 0.42 
28 0.04 -0.03 14.76 3.41 -2.27 5.15 -0.83 0.69 
60 0.08 -0.02 13.19 3.65 -3.84 14.75 -1.84 3.39 
91 0.11 0.00 11.74 3.69 -5.29 27.97 -2.20 4.84 
120 0.13 0.02 10.94 4.08 -6.09 37.08 -2.89 8.35 
150 0.16 0.16 10.39 -6.64 -6.64 44.09 -3.53 12.46 
Average:   0.01   3.03   644.70   36.97 
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Predictive Model Day 1-150 
y = 0.0032x0.7449 
Day 
Predicted 
Cumulative 
Release 
Difference 
from 
Experimental 
Cumulative 
Predicted 
Release Rate 
Difference From 
Experimental 
Release Rate SSR SSR SSE SSE 
1 0.00 0.00 38.82 0.52 21.79 474.91 -2.14 4.59 
2 0.01 0.00 26.24 -2.10 9.21 84.80 -1.82 3.31 
4 0.01 0.00 21.99 0.31 4.96 24.56 0.07 0.01 
7 0.01 0.00 18.80 0.72 1.77 3.12 2.41 5.82 
14 0.02 0.00 15.97 2.16 -1.06 1.12 2.04 4.15 
22 0.03 0.01 13.87 2.76 -3.16 9.98 1.31 1.71 
28 0.04 0.01 12.73 2.93 -4.30 18.47 1.20 1.43 
60 0.07 0.04 11.10 4.14 -5.93 35.22 0.25 0.06 
91 0.09 0.06 9.62 2.96 -7.41 54.93 -0.08 0.01 
120 0.11 0.08 8.82 2.72 -8.21 67.40 -0.77 0.59 
150 0.13 0.10 8.28 2.21 -8.75 76.57 -1.42 2.02 
Average:  0.03  1.76  851.07  23.71 
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Appendix C 
Second Generation Model 
 
Figure 1 Application of Korsmeyers-Peppas Predictions to 20% Drug Loaded Devices under 
72hour 60C Water Wash. 
An entirely empirically based model was developed in order to achieve the highest 
degree of accuracy.  Previously, model developments were based on Korsmeyer-Peppas fit 
which utilized the cumulative release faction in order to elucidate the release mechanism. The 
newest model was still based on the power function in order to ease its application. 
The old model, shown above, resulted in a higher predicted value for day 180 release 
rate. This error in prediction indicated a change in the mechanism of release and required a 
second generation model to be developed. This model would be broken down into two parts: 
one for initial time points of the curve during which release is diffusion controlled, the other for 
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the later part of the curve during which release is not diffusion controlled, and then combined 
to form a final model. 
In this case, a model was produced with both the release rate and cumulative fraction in 
order to produce the most accurate predictive model. Model developments are shown below. 
Model 3 Final 
y = 36.412x-0.297 
  
Empirical Release 
Rate 
Theoretical 
Release Rate 
Difference from 
Real 
1 33.18 36.41 3.23 
2 27.90 29.64 -0.54 
4 23.46 24.12 0.66 
7 20.40 20.43 -1.49 
14 17.15 16.63 -3.13 
21 15.50 14.74 -3.06 
28 14.42 13.53 -2.27 
35 13.64 12.67 -1.53 
42 13.03 12.00 -1.60 
49 12.54 11.46 -1.14 
56 12.13 11.02 -0.78 
63 11.78 10.64 -0.56 
70 11.47 10.31 -0.29 
84 10.96 9.77 0.17 
91 8.57 9.54 -0.06 
107 8.17 9.09 0.09 
120 7.89 8.78 0.38 
133 7.65 8.52 0.52 
150 7.38 8.22 0.82 
179 7.00 7.80 1.00 
 
76 
 
Predictive Model Day 1-180 
y = 36.412x-0.297 
y = 
0.0032x0.7449 
Predicted 
Release 
Rate 
Difference 
From 
Experimental 
Release Rate SSR SSR SSE SSE 
1 36.41 3.23 22.20 492.80 3.23 10.43 
2 29.64 -0.54 15.43 238.05 1.74 3.03 
4 24.12 0.66 9.91 98.19 0.66 0.44 
7 20.43 -1.49 6.22 38.68 0.03 0.00 
14 16.63 -3.13 2.42 5.85 -0.52 0.27 
21 14.74 -3.06 0.53 0.28 -0.76 0.58 
28 13.53 -2.27 -0.68 0.46 -0.89 0.79 
35 12.67 -1.53 -1.54 2.37 -0.97 0.94 
42 12.00 -1.60 -2.21 4.89 -1.03 1.06 
49 11.46 -1.14 -2.75 7.57 -1.08 1.17 
56 11.02 -0.78 -3.19 10.18 -1.11 1.23 
63 10.64 -0.56 -3.57 12.75 -1.14 1.30 
70 10.31 -0.29 -3.90 15.22 -1.16 1.35 
84 9.77 0.17 -4.44 19.72 -1.19 1.42 
91 9.54 -0.06 -4.67 21.82 0.97 0.94 
107 9.09 0.09 -5.12 26.22 0.92 0.85 
120 8.78 0.38 -5.43 29.50 0.89 0.79 
133 8.52 0.52 -5.69 32.39 0.87 0.76 
150 8.22 0.82 -5.99 35.89 0.84 0.71 
179 7.80 1.00 -6.41 41.10 0.80 0.64 
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Figure 2 The newly derived model is >95% accurate, when applying a directly applied model to 
the empirically derived data and is not susceptible to outliers.  
y = 36.412x-0.297
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